Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Time to Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $15.04, but opened at $14.20. Keros Therapeutics shares last traded at $14.60, with a volume of 556,990 shares changing hands.

Analyst Ratings Changes

KROS has been the topic of several recent research reports. Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Truist Financial decreased their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the company from $32.00 to $18.00 in a research report on Tuesday. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.56.

Keros Therapeutics Trading Down 1.1%

The company has a market capitalization of $553.99 million, a PE ratio of -2.62 and a beta of 1.31. The stock's 50-day moving average is $13.66 and its two-hundred day moving average is $17.41.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. During the same period in the prior year, the company posted ($1.21) EPS. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 20.60% of the company's stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock worth $26,151,000 after acquiring an additional 609,212 shares during the period. Braidwell LP boosted its stake in shares of Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after purchasing an additional 1,187,199 shares in the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after purchasing an additional 163,403 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company's stock valued at $15,147,000 after purchasing an additional 1,463,215 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock valued at $12,474,000 after purchasing an additional 1,099,519 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.